Taimei Medical Technology (02576) plans to invest 70 million yuan to participate in a partnership

Zhitong Finance App News, Taimei Medical Technology (02576) announced that on December 24, 2025 (after the transaction period), the company (as limited partner), Taimei Zhiyan (as limited partner), Jiaxing Industrial Investment (as limited partner), Mr. Lu Gaofeng (as limited partner), Ms. Lu Haixiao (as limited partner), Ms. Chen Guojuan (as limited partner), and Kaifeng Taimei (as general partner) entered into a partnership agreement on December 24, 2025 (after the transaction period). The total initial capital injection of all partners into the partnership will be RMB 227.27 million, of which the company, Taimei Zhiyan, Jiaxing Industrial Investment, Mr. Lu Gaofeng, Ms. Lu Haixiao, Ms. Chen Guojuan, and Kaifeng Taimei will invest RMB 70 million, RMB 30 million, RMB 100 million, RMB 10 million, RMB 2.27 million, RMB 2.27 million respectively. The partnership will prioritize investment in companies located in the Jiaxing Economic and Technological Development Zone.

The board of directors believes that through the establishment of a partnership company, it can deeply participate in the research and development of innovative drug pipelines, and the company will be able to standardize and modularly export its digital medicine R&D solutions to each innovative drug R&D pipeline in the early stages of growth, thus having the opportunity to share the excess benefits of successful drug development and expand the company's industry footprint; secondly, seize key links in the industry value chain through partnership holding pipeline interests and participate in early clinical trials to seize key links in the industry value chain, avoid the complexity and long-term risks of traditional equity investment, and achieve efficient exit through transfer or sale pipelines. Fast turnaround and value delivery.